Please assess the completion status of the following clinical trial:

Trial Title: Study on Safety and Clinical Efficacy of AZVUDINE in Initial Stage COVID-19 Patients (SARS-CoV-2 Infected)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Individuals who present the following characteristics will be included in this study:~1. Age ≥18 years, regardless of gender;~2. Fluorescence RT-PCR test result of respiratory or blood samples must be positive for COVID-19, or viral gene sequencing of respiratory tract samples must be highly homologous to COVID-19; Individuals with COVID-19 must meet the diagnostic criteria in the latest version of clinical guidelines for COVID-19 issued by the World Health Organization (WHO) on June 4, 2020;~3. Symptomatic patients who meet the case definition for COVID-19, according to WHO, without evidence of bacterial pneumonia or hypoxia (Sat O2 \< 95%) P. \[score 1-3\];~4. Voluntary participation and signing of the informed consent form.~Exclusion Criteria:~Individuals who present one or more of the following characteristics will not be eligible to participate in this study:~1. Know or suspect that you are allergic to any of the components of AZVUDINE tablets (inactive ingredients: microcrystalline cellulose, lactose hydrate, polyvinylpyrrolidone K30, croscarmellose sodium, magnesium stearate);~2. Individual presenting shortness of breath and Sat O2 \< 95%; or any other symptom requiring treatment through hospital admission;~3. Patients with liver disease (total bilirubin ≥2mg/dL, ALT/TGP e AST/TGO ≥5 times above normal limit);~4. Pactients with a history of known liver disease (cirrhosis with ChildPugh classification B and C);~5. Patients with a history of renal insufficiency (glomerular filtration rate \< 60mL/min/1,73m2);~6. Patients with history of congestive heart failure (NYHA ¾ grade), untreated symptomatic arrhythmias ormyocardial infarction within 6 months;~7. Individuals with malabsorption syndrome, or other conditions affecting gastrointestinal absorption, and circumstances in which patients require intravenous nutrition, or cannot take medications orally or nasogastrically;~8. Total neutrophil count \<750 cells/L;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AZVUDINE (Type: EXPERIMENTAL): Experimental:~AZVUDINE 1mg tablet~Interventions:~AZVUDINE 1mg tablet, 5 tablets QD + standard treatment, for up to 14 days
- AZVUDINE placebo (Type: PLACEBO_COMPARATOR): Control:~AZVUDINE placebo~Intervention:~AZVUDINE placebo tablet, 5 tablets QD + standard treatment, for up to 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).